Liselotte Sabroe | Afp | Getty Photos
Novo Nordisk on Wednesday reported better-than-anticipated 2023 earnings, as gross sales of its wildly neatly-liked anti-weight problems and diabetes remedy persevered to wing.
The maker of weight reduction drug Wegovy and diabetes drug Ozempic reported an amplify in gross sales of 31% in Danish kroner and 36% at fixed substitute rates (CER) to 232.3 billion kroner ($33.71 billion).
Full-twelve months working profit jumped by 37% in kroner and 44% at fixed substitute rates to 102.6 billion kroner.
The Danish pharmaceutical massive acknowledged it expects gross sales development this twelve months of between 18% and 26% in CER terms, as query surges for Wegovy and Ozempic, which have the a related intelligent ingredient.
Novo Nordisk’s valuation rose to $506 billion at 08:06 GMT, basically basically basically based on CNBC’s calculation of LSEG records. The fragment save moderated somewhat throughout the session, and became once up by 1.3% on the day at 1:05 p.m. London time.
Novo remains Europe’s greatest firm by market capitalization, forward of LVMH, which became once valued at $422 billion forward of Wednesday’s market open.
The 2023 outcomes have been fueled by noteworthy performance in the firm’s diabetes and weight problems care division, with weight problems care in explicit spiking by 154% at CER to 41.6 billion.
“We genuinely ask the a related stage of query in the current twelve months and whereas you happen to stare upon the indisputable fact that we are handiest serving a couple of million patients residing with weight problems, some 40 million people residing with diabetes — there is a gargantuan market available,” CEO Lars Fruergaard Jørgensen told CNBC on Wednesday.
Competition in the burden-loss speed has emerged for Novo Nordisk in the fabricate of U.S. stalwart Eli Lilly. The Danish firm has acknowledged here’s likely to bring downward save pressures in the U.S., though Jørgensen acknowledged the competition would after all merit patients.
“Whilst you is possibly in truth going to scheme a large dent in treating people with weight problems and preventing about a of the prepare-on ailments from that, it genuinely takes extra than one firm to end that, so I welcome competition that will encourage save the weight problems market,” he told CNBC’s Charlotte Reed on Wednesday.
“We’re ragged to competing on having the handiest merchandise, and the incoming competitor we have gotten been competing with for over 100 years — we have gotten gargantuan appreciate for each and each other — so that is the wholesome competition that genuinely brings better and better care to patients and takes the burden off health care societies. So I comprise or not it is a receive-receive for not handiest the two companies, nonetheless furthermore for society.”
While costs can also need to achieve down, Novo Nordisk does not survey a slowdown in global query.
“The unmet wants in form 2 diabetes and weight problems are rising by the day, and the rising prevalence of these carefully related threats to global health has created surging query for our GLP-1-basically basically basically based therapies,” Jørgensen and Chairman Helge Lund acknowledged in Wednesday’s earnings file.
“This has enabled us to effect extra patients than at any point in our 100-twelve months historical previous, contributing to noteworthy gross sales development all over North America and World Operations.”
The firm furthermore acknowledged that this had resulted in elevated stress on its supply chain, ensuing in “periodic constraints” all over its portfolio because it struggled to protect glide with query in 2023.
“We have answered by investing carefully in expanding our production ability with the objective of serving hundreds and hundreds extra patients worldwide. In 2023 on my own, we presented investments totalling extra than DKK 75 billion in the growth of our production net sites all around the globe,” the chairman and CEO acknowledged.
“With constructing now underway on these projects, we are attempting to operate our current companies 24 hours a day, seven days per week, as we construct extra of our life-altering medicines than ever before.”
Novo Nordisk acknowledged it had now begun to gradually amplify supply of lower dosage Wegovy in the U.S., having restricted supply of the starter dose strength since final Might possibly also.
